[Skip to Navigation]
Sign In
Comment & Response
March 2016

Treatment and Long-Term Risks for Patients With a Diagnosis of Ductal Carcinoma In Situ

Author Affiliations
  • 1Dr Susan Love Research Foundation, Santa Monica, California
  • 2David Geffen School of Medicine at UCLA, Los Angeles, California
JAMA Oncol. 2016;2(3):398-399. doi:10.1001/jamaoncol.2015.4866

To the Editor The recent article by Narod et al1 notes that 3% of women who have received a diagnosis of ductal carcinoma in situ (DCIS) die of breast cancer. This figure is independent of whether they have had a local recurrence of invasive disease or in situ disease. I would suggest that the study has identified the small subgroup of pseudo-DCIS, that is, noninvasive breast cancer that is masquerading as invasive through neoductogenesis.

Add or change institution